Landos Biopharma Statistics Share Statistics Landos Biopharma has 3.13M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 3.13M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 1.33M Failed to Deliver (FTD) Shares 4 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 647, so 0% of the outstanding
shares have been sold short.
Short Interest 647 Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.05 and the forward
PE ratio is -19.27.
Landos Biopharma's PEG ratio is
0.02.
PE Ratio -1.05 Forward PE -19.27 PS Ratio 0 Forward PS 71.7 PB Ratio 0.72 P/FCF Ratio -1.12 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Landos Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.09,
with a Debt / Equity ratio of 0.
Current Ratio 6.09 Quick Ratio 6.09 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.15M Employee Count 19 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.14, so Landos Biopharma's
price volatility has been higher than the market average.
Beta 0.14 52-Week Price Change n/a 50-Day Moving Average 19.89 200-Day Moving Average 8.25 Relative Strength Index (RSI) 77.26 Average Volume (20 Days) 27,036
Income Statement
Revenue n/a Gross Profit n/a Operating Income -22.73M Net Income -21.93M EBITDA -22.73M EBIT -22.73M Earnings Per Share (EPS) -3.5
Full Income Statement Balance Sheet The company has 37.55M in cash and 0 in
debt, giving a net cash position of 37.55M.
Cash & Cash Equivalents 37.55M Total Debt n/a Net Cash n/a Retained Earnings -155.36M Total Assets 29.9M Working Capital 23.15M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -20.48M
and capital expenditures 0, giving a free cash flow of -20.48M.
Operating Cash Flow -20.48M Capital Expenditures n/a Free Cash Flow -20.48M FCF Per Share -3.26
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields LABP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for LABP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 26, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date May 26, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -3.17 Piotroski F-Score 2
